Phase 2, Phase 3 Recruiting NIH
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
- UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- Jefferson Torresdale Hospital — Philadelphia, Pennsylvania
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Pennsylvania: - Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus — Harrisburg, Pennsylvania
Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Pennsylvania: - Site 151 — Bensalem, Pennsylvania
- Site 158 — Philadelphia, Pennsylvania
- Site 159 — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Pennsylvania: - Site 43 — Philadelphia, Pennsylvania
- Site 153 — Philadelphia, Pennsylvania
- Site 154 — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Pennsylvania: - GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Pennsylvania: - Fox Chase Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center - Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Pennsylvania: - University of Pennsylvania, Perelman School of Medicine — Philadelphia, Pennsylvania
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Jefferson Torresdale Hospital — Philadelphia, Pennsylvania
- Asplundh Cancer Pavilion — Willow Grove, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Pennsylvania: - UPMC Altoona — Altoona, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
- IRMC Cancer Center — Indiana, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…
Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Pennsylvania: - Chambersburg Hospital — Chambersburg, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
- Adams Cancer Center — Gettysburg, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …
Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in Pennsylvania: - UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- UPMC Hillman Cancer Center at Butler Health System — Butler, Pennsylvania
- UPMC Camp Hill — Camp Hill, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Pennsylvania: - UPMC — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Pennsylvania: - Avenzo Therapeutics Recruiting Site — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Pennsylvania: - Cancer Care Associates of York (site 206) — York, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Pennsylvania: - Asplundh Cancer Pavilion — Willow Grove, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06123338
Sites in Pennsylvania: - University of Pennsylvania (Data Collection Only) — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Pennsylvania: - Research Site — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania